HP Delivers Innovations to Public Health with New CDC Pilot Program

News highlights

• CDC launches HP pilot program with the purchase of HP BioPrinters for four regional labs in New York, Minnesota, Tennessee, and Wisconsin.
• HP BioPrinters, with inkjet printing technology, adapted for automated laboratory dispensing to help fight antimicrobial resistance.
• Makes testing of new antibiotics possible at the local level for the first time.

PALO ALTO, Calf., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Today HP Inc. announced its participation in a pilot program run by the Centers for Disease Control and Prevention (CDC) that aims to accelerate the testing of new antibiotics designed to fight antimicrobial resistant bacteria. The pilot uses HP technology to “print” pharmaceutical samples. As part of the pilot, CDC will deploy new to four regional labs in the , to develop antimicrobial susceptibility test methods for new drugs. For the first time, regional labs will be able to conduct rapid susceptibility testing for health departments and hospitals nationwide.

“Bacteria continuously develop new ways to resist antibiotics—once a drug is approved for use, the countdown begins until resistance emerges. In fact, resistance has even been detected before FDA approval,” said Jean Patel, PH.D. D (ABMM), Science Team Lead, Antibiotic Resistance Coordination and Strategy Unit at CDC. “To save lives and protect people, it is vital to make technology accessible to hospital labs nationwide. We hope this pilot will help ensure our newest drugs last longer and put gold-standard lab results in healthcare providers’ hands faster.”

Antimicrobial resistance is an international public health issue. New antibiotics for resistant bacteria can help save lives, but hospitals often do not have access to antimicrobial susceptibility testing to know if the new drug might be effective.  The HP printer helps to speed up testing availability at the local level by “printing” the gold standard test plates in a few minutes. When testing is not available, new drugs can be either overutilized, contributing to antimicrobial resistance, underutilized, not helping patients in need, or misutilized, which can lead to side effects or prolonged treatment.

How it Works

The BioPrinter accurately dispenses or “prints” volumes from picoliters to microliters for faster, more reliable dispensing of small molecules and biomolecules to enable drug discovery, genomics, and proteomics research.  The following labs within the AR Lab Network will use this technology to develop and perform antimicrobial susceptibility testing for new drugs: New York, Minnesota, Tennessee and Wisconsin. This new capacity can be used by healthcare providers for patient care while commercial methods commonly used in hospital laboratories are developed and implemented.

Testing through CDC will be implemented in the regional laboratories in the first quarter of FY19. CDC will prioritize testing for highly resistant bacteria, with pan-resistant bacteria being the top priority. HP will coordinate with CDC to evaluate the pilot in the regional laboratories of the AR Regional Lab Network, refine the system, and explore and support a larger rollout of inkjet printing technology in labs nationwide.

To learn more, visit: /go/bioprint.

About HP

HP Inc. creates technology that makes life better for everyone, everywhere. Through our portfolio of printers, PCs, mobile devices, solutions and services, we engineer experiences that amaze. More information about HP Inc. is available at

© 2018 HP Development Company LP. The information contained herein is subject to change without notice. The only warranties for HP Inc. products and services are set forth in the express warranty statements accompanying such products and services. Nothing herein should be construed as constituting an additional warranty. HP Inc. shall not be liable for technical or editorial errors or omissions contained herein.

Photos accompanying this announcement are available at

A video accompanying this release is available at